Influence of the Circadian System on Disease Severity

Sleep Medicine Clinics

Volumn 4, Issue 2, 2009, Pages 143-163

  Litinski, Mikhail ^a   Scheer, Frank A J L ^a   Shea, Steven A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Asthma; Cardiovascular; Chronotherapy; Circadian; Epilepsy; Sleep

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BAMBUTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; LONG ACTING DRUG; MELATONIN; MONTELUKAST; NIFEDIPINE; NITRIC ACID DERIVATIVE; ORCIPRENALINE; PLACEBO; PROPRANOLOL; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TRIAMCINOLONE; UNINDEXED DRUG; VERAPAMIL;

ADD ON THERAPY; ALZHEIMER DISEASE; ANGINA PECTORIS; ASTHMA; BEDTIME DOSAGE; BIOLOGICAL RHYTHM; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; EPILEPSY; EVENING DOSAGE; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEART INFARCTION; HOARSENESS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG FUNCTION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MOLECULAR CLOCK; MORNING DOSAGE; NONHUMAN; OROPHARYNX CANDIDIASIS; PRINZMETAL ANGINA PECTORIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPRODUCTIVE HEALTH; REVIEW; SHIFT WORKER; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP; SLEEP WAKING CYCLE; SUPRAVENTRICULAR TACHYCARDIA; SYMPATHETIC TONE;

EID: 66549129438     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2009.02.005     Document Type: Review

References (234)

1. Cohen M.C., Rohtla K.M., Lavery C.E., et al. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 79 11 (1997) 1512-1516
2. Ogawa H., Yasue H., Oshima S., et al. Circadian variation of plasma fibrinopeptide a level in patients with variant angina. Circulation 80 6 (1989) 1617-1626
3. Deedwania P.C. Circadian rhythms of cardiovascular disorders (1997), Futura Publishing Company, Inc, Armonk (NY)
4. Rocco M.B., Barry J., Campbell S., et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 75 2 (1987) 395-400
5. Arntz H.R., Willich S.N., Oeff M., et al. Circadian variation of sudden cardiac death reflects age-related variability in ventricular fibrillation. Circulation 88 5 Pt 1 (1993) 2284-2289
6. Shea S.A., Hilton M.F., and Muller J.E. Day/night patterns of myocardial infarction and sudden cardiac death: interacting roles of the endogenous circadian system and behavioral triggers. In: White W.B. (Ed). Blood pressure monitoring in cardiovascular medicine and therapeutics. 2nd ed (2007), Humana Press Inc., Totowa (NJ) 251-289
7. Canada W.B., Woodward W., Lee G., et al. Circadian rhythm of hourly ventricular arrhythmia frequency in man. Angiology 34 4 (1983) 274-282
8. Twidale N., Taylor S., Heddle W.F., et al. Morning increase in the time of onset of sustained ventricular tachycardia. Am J Cardiol 64 18 (1989) 1204-1206
9. Valkama J.O., Huikuri H.V., Linnaluoto M.K., et al. Circadian variation of ventricular tachycardia in patients with coronary arterial disease. Int J Cardiol 34 2 (1992) 173-178
10. Rebuzzi A.G., Lucente M., Lanza G.A., et al. Circadian rhythm of ventricular tachycardia. Prog Clin Biol Res 227B (1987) 153-158
11. d'Avila A., Wellens F., Andries E., et al. At what time are implantable defibrillator shocks delivered? Evidence for individual circadian variance in sudden cardiac death. Eur Heart J 16 9 (1995) 1231-1233
12. Behrens S., Galecka M., Bruggemann T., et al. Circadian variation of sustained ventricular tachyarrhythmias terminated by appropriate shocks in patients with an implantable cardioverter defibrillator. Am Heart J 130 1 (1995) 79-84
13. Mallavarapu C., Pancholy S., Schwartzman D., et al. Circadian variation of ventricular arrhythmia recurrences after cardioverter-defibrillator implantation in patients with healed myocardial infarcts. Am J Cardiol 75 16 (1995) 1140-1144
14. Fries R., Heisel A., Huwer H., et al. Incidence and clinical significance of short-term recurrent ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillator. Int J Cardiol 59 3 (1997) 281-284
15. Tofler G.H., Gebara O.C., Mittleman M.A., et al. Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. The CPI Investigators. Circulation 92 5 (1995) 1203-1208
16. Nanthakumar K., Newman D., Paquette M., et al. Circadian variation of sustained ventricular tachycardia in patients subject to standard adrenergic blockade. Am Heart J 134 4 (1997) 752-757
17. Venditti Jr. F.J., John R.M., Hull M., et al. Circadian variation in defibrillation energy requirements. Circulation 94 7 (1996) 1607-1612
18. Staessen J.A., Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282 6 (1999) 539-546
19. Uzu T., Fujii T., Nishimura M., et al. Determinants of circadian blood pressure rhythm in essential hypertension. Am J Hypertens 12 1 Pt 1 (1999) 35-39
20. Uzu T., Ishikawa K., Fujii T., et al. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 96 (1997) 1859-1862
21. Kimura G., Uzu T., Nakamura S., et al. High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism. J Hypertens 14 12 (1996) 1463-1468
22. Kario K., Motai K., Mitsuhashi T., et al. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation-relation to silent cerebrovascular disease. Hypertension 30 6 (1997) 1504-1510
23. Millar-Craig M.W., Bishop C.N., and Raftery E.B. Circadian variation of blood-pressure. Lancet 1 8068 (1978) 795-797
24. Floras J.S., Jones J.V., Johnston J.A., et al. Arousal and the circadian rhythm of blood pressure. Clin Sci Mol Med Suppl 4 (1978) 395s-397s
25. Mancia G., Ferrari A., Gregorini L., et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53 1 (1983) 96-104
26. Somers V.K., Phil D., Dyken M.E., et al. Sympathetic-nerve activity during sleep in normal subjects. N Eng J Med 328 (1993) 303-307
27. Kirby D.A., and Verrier R.L. Differential effects of sleep stage on coronary hemodynamic function during stenosis. Physiol Behav 45 5 (1989) 1017-1020
28. Turton M.B., and Deegan T. Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta 55 3 (1974) 389-397
29. Deedwania P.C., and Nelson J.R. Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation 82 4 (1990) 1296-1304
30. Andrews T.C., Fenton T., Toyosaki N., et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 88 1 (1993) 92-100
31. Undar L., Turkay C., and Korkmaz L. Circadian variation in circulating platelet aggregates. Ann Med 21 6 (1989) 429-433
32. Undar L., Ertugrul C., Altunbas H., et al. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 81 4 (1999) 571-575
33. Haus E., Cusulos M., Sackett-Lundeen L., et al. Circadian variations in blood coagulation parameters, alpha-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int 7 3 (1990) 203-216
34. Jovicic A., Ivanisevic V., and Nikolajevic R. Circadian variations of platelet aggregability and fibrinolytic activity in patients with ischemic stroke. Thromb Res 64 4 (1991) 487-491
35. Tofler G.H., Stone P.H., Maclure M., et al. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 66 1 (1990) 22-27
36. Andrews N.P., Goldstein D.S., and Quyyumi A.A. Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects. Am J Cardiol 84 3 (1999) 316-320
37. Willich S.N., Tofler G.H., Brezinski D.A., et al. Platelet alpha 2 adrenoceptor characteristics during the morning increase in platelet aggregability. Eur Heart J 13 4 (1992) 550-555
38. Del Zar M.M., Martinuzzo M., Falcon C., et al. Inhibition of human platelet aggregation and thromboxane-B2 production by melatonin: evidence for a diurnal variation. J Clin Endocrinol Metab 70 1 (1990) 246-251
39. Krauchi K., and Wirz-Justice A. Circadian rhythm of heat production, heart rate, and skin and core temperature under unmasking conditions in men. Am J Physiol 267 3 Pt 2 (1994) R819-R829
40. Burgess H.J., Trinder J., Kim Y., et al. Sleep and circadian influences on cardiac autonomic nervous system activity. Am J Physiol 273 4 Pt 2 (1997) H1761-H1768
41. Kerkhof G.A., Dongen H., and Bobbert A.C. Absence of endogenous circadian rhythmicity in blood pressure?. Am J Hypertens 11 3 (1998) 373-377
42. Hu K., Ivanov P., Hilton M.F., et al. Endogenous circadian rhythm in an index of cardiac vulnerability independent of changes in behavior. Proc Natl Acad Sci U S A 101 52 (2004) 18223-18227
43. Scheer F.A.J.L., Ter Horst G.J., Van der Vliet J., et al. Physiological and anatomic evidence for regulation of the heart by suprachiasmatic nucleus in rats. Am J Physiol 280 3 (2001) H1391-H1399
44. Hu K., Scheer F.A., Buijs R.M., et al. The endogenous circadian pacemaker imparts a scale-invariant pattern of heart rate fluctuations across time scales spanning minutes to 24 hours. J Biol Rhythms 23 3 (2008) 265-273
45. Scheer F.A., Hu K., Evoniuk H., et al. Additive influences of the endogenous circadian system and mental stress on cardiovascular risk factors. Sleep 31 Suppl (2008) S51
46. Scheer F.A., Hu K., Evoniuk H., et al. Influence of endogenous circadian system, physical exercise and their interaction on cardiovascular risk factors. Sleep 31 suppl (2008) S46
47. Cutler N.R., Anders R.J., Jhee S.S., et al. Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. Am J Cardiol 75 16 (1995) 1102-1106
48. Frishman W.H., Glasser S., Stone P., et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 83 4 (1999) 507-514
49. Prisant L.M., Devane J.G., and Butler J. A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours. Am J Ther 7 6 (2000) 345-351
50. Smith D.H., Neutel J.M., and Weber M.A. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens 14 1 (2001) 14-19
51. Prisant Lm W.H., and Black. Role of circadian rhtyhm in cardiovascular function-efficacy of a chronotherapeutic approach to controlling hypertensionwith Verelan PM (verapamil HCL). Todays Ther Trends 21 (2003) 201-213
52. Glasser S.P., Neutel J.M., Gana T.J., et al. Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension. Am J Hypertens 16 1 (2003) 51-58
53. Glasser S.P., Gana T.J., Pascual L.G., et al. Efficacy and safety of a once-daily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. Am Heart J 149 2 (2005) e1-e9
54. Spengler C.M., Czeisler C.A., and Shea S.A. An endogenous circadian rhythm of respiratory control in humans. J Physiol 526 3 (2000) 683-694
55. Muller J.E., Stone P.H., Turi Z.G., et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 21 (1985) 1315-1322
56. Cohn P.F., and Lawson W.E. Effects of long-acting propranolol on A.M. and P.M. peaks in silent myocardial ischemia. Am J Cardiol 63 12 (1989) 872-873
57. Sica D., Frishman W.H., and Manowitz N. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL), a new chronotherapeutic formulation. Heart Dis 5 3 (2003) 176-181
58. Scheer F.A.J.L., Cajochen C., Turek F.W., et al. Melatonin in the regulation of sleep and circadian rhythms. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and practice of sleep medicine. 4th edition (2005), W.B. Saunders, Philadelphia 395-404
59. Yasue H., Omote S., Takizawa A., et al. Circadian variation of exercise capacity in patients with Prinzmetal's variant angina: role of exercise-induced coronary arterial spasm. Circulation 59 5 (1979) 938-948
60. Wortman A.B. Chronotherapy in coronary heart disease: comparison of two nitrate treatments. Chronobiol Int 8 (1991) 399-408
61. Ridker P.M., Manson J.E., Buring J.E., et al. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 82 3 (1990) 897-902
62. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 13 (2005) 1293-1304
63. Cornelissen G., Halberg F., Prikryl P., et al. Prophylactic aspirin treatment: the merits of timing. International Womb-to-Tomb Chronome Study Group. JAMA 266 22 (1991) 3128-3129
64. Reinberg A., Zagula-Mally Z.W., Ghata J., et al. Circadian rhythm in duration of salicylate excretion referred to phase of excretory rhythms and routine. Proc Soc Exp Biol Med 124 3 (1967) 826-832
65. Markiewicz A., and Semenowicz K. Time dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm 17 10 (1979) 409-411
66. Shibasaki T., Obara T., Ohkubo T., et al. Time-dependent effects of imidapril administration in patients with morning hypertension measured as home blood pressure. Clin Exp Hypertens 30 3 (2008) 243-254
67. Kohno I., Ijiri H., Takusagawa M., et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int 17 2 (2000) 209-219
68. Dagenais G.R., Pogue J., Teo K.K., et al. Impact of ramipril on the circadian periodicity of acute myocardial infarction. Am J Cardiol 98 6 (2006) 758-760
69. Hermida R.C., Calvo C., Ayala D.E., et al. Relationship between physical activity and blood pressure in dipper and non-dipper hypertensive patients. J Hypertens 20 6 (2002) 1097-1104
70. Ohkubo T., Imai Y., Tsuji I., et al. Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens 10 11 (1997) 1201-1207
71. Jonas M., Garfinkel D., Zisapel N., et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 12 1 (2003) 19-24
72. Scheer F.A.J.L., van Montfrans G.A., Van Someren E.J.W., et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43 2 (2004) 192-197
73. Cagnacci A., Cannoletta M., Renzi A., et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am J Hypertens (2005)
74. Bohadana A.B., Hannhart B., and Teculescu D.B. Nocturnal worsening of asthma and sleep-disordered breathing. J Asthma 39 2 (2002) 85-100
75. Global Initiative for asthma (GINA). Global strategy for asthma management and prevention. NHLBI/WHO Workshop report (1995), Lung and Blood Institute, Bethesda MNH. Available at: http://www.ginasthma.com/ReportItem.asp?l1=2&l2=2&intId=96 [updated March, 2002]. Accessed September 1, 2008
76. Hetzel M.R., Clark T.J., and Branthwaite M.A. Asthma: analysis of sudden deaths and ventilatory arrests in hospital. Br Med J 1 6064 (1977) 808-811
77. Masoli M., Fabian D., Holt S., et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 5 (2004) 469-478
78. Martin R.J., Cicutto L.C., Smith H.R., et al. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 143 2 (1991) 351-357
79. Kraft M., Djukanovic R., Wilson S., et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 154 5 (1996) 1505-1510
80. Smolensky M.H., Barnes P.J., Reinberg A., et al. Chronobiology and asthma. I. Day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies. J Asthma 23 6 (1986) 321-343
81. Hetzel M.R., and Clark T.J. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 35 10 (1980) 732-738
82. Bonnet R., Jorres R., Heitmann U., et al. Circadian rhythm in airway responsiveness and airway tone in patients with mild asthma. J Appl Physiol 71 4 (1991) 1598-1605
83. Gervais P., Reinberg A., Gervais C., et al. Twenty-four-hour rhythm in the bronchial hyperreactivity to house dust in asthmatics. J Allergy Clin Immunol 59 3 (1977) 207-213
84. Jarjour N.N. Circadian variation in allergen and nonspecific bronchial responsiveness in asthma. Chronobiol Int 16 5 (1999) 631-639
85. Morrison J.F., Pearson S.B., and Dean H.G. Parasympathetic nervous system in nocturnal asthma. Br Med J (Clin Res Ed) 296 6634 (1988) 1427-1429
86. Barnes P., FitzGerald G., Brown M., et al. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med 303 5 (1980) 263-267
87. Khatri I.M., and Freis E.D. Hemodynamic changes during sleep. J Appl Physiol 22 5 (1967) 867-873
88. Hornyak M., Cejnar M., Elam M., et al. Sympathetic muscle nerve activity during sleep in man. Brain 114 3 (1991) 1281-1295
89. Soutar C.A., Costello J., Ijaduola O., et al. Nocturnal and morning asthma. Relationship to plasma corticosteroids and response to cortisol infusion. Thorax 30 4 (1975) 436-440
90. Kraft M., Martin R.J., Wilson S., et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 159 1 (1999) 228-234
91. Kraft M., Vianna E., Martin R.J., et al. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol 103 1 Pt 1 (1999) 66-71
92. Kraft M., Hamid Q., Chrousos G.P., et al. Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible?. Am J Respir Crit Care Med 163 5 (2001) 1219-1225
93. Spengler C.M., and Shea S.A. Endogenous circadian rhythm of pulmonary function in healthy humans. Am J Respir Crit Care Med 162 3 Pt 1 (2000) 1038-1046
94. Shea S.A., Scheer F.A., and Hilton M.F. Predicting the daily pattern of asthma severity based on relative contributions of the circadian timing system, the sleep-wake cycle and the environment. Sleep 30 suppl (2007) S65
95. Shea Sa H.M., Scheer F.A.J.L., Ayers R.T., et al. An endogenous circadian rhythm in bronchodilators rescue medication use in asthma. Sleep 27 suppl (2004) S81
96. National Asthma Education and Prevention Program (NAEPP). Guidelines for the diagnosis and management of asthma: expert panel report 2 (1997), Lung, and Blood Institute, Bethesda MNH
97. Darow P.S.V. Therapeutic advantage of unequal dosing of theophylline in patients with nocturnal asthma. Chronobiol Int 4 (1987) 349-357
98. Smolensky M.H., Scott P.H., Harrist R.B., et al. Administration-time-dependency of the pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children. Chronobiol Int 4 3 (1987) 435-447
99. D'Alonzo G.E., Smolensky M.H., Feldman S., et al. Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis 142 1 (1990) 84-90
100. Neuenkirchen H., Wilkens J.H., Oellerich M., et al. Nocturnal asthma: effect of a once per evening dose of sustained release theophylline. Eur J Respir Dis 66 3 (1985) 196-204
101. Reinberg A., Pauchet F., Ruff F., et al. Comparison of once-daily evening versus morning sustained-release theophylline dosing for nocturnal asthma. Chronobiol Int 4 3 (1987) 409-419
102. Kraft M., Torvik J.A., Trudeau J.B., et al. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 97 6 (1996) 1242-1246
103. Reinberg A., Guillet P., Gervais P., et al. One month chronocorticotherapy (Dutimelan 8 15 mite). Control of the asthmatic condition without adrenal suppression and circadian rhythm alteration. Chronobiologia 4 4 (1977) 295-312
104. Beam W.R., Weiner D.E., and Martin R.J. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am Rev Respir Dis 146 6 (1992) 1524-1530
105. Reinberg A., Gervais P., Chaussade M., et al. Circadian changes in effectiveness of corticosteroids in eight patients with allergic asthma. J Allergy Clin Immunol 71 4 (1983) 425-433
106. Ceresa F., Angeli A., Boccuzzi G., et al. Once-a-day neurally stimulated and basal ACTH secretion phases in man and their response to corticoid inhibition. J Clin Endocrinol Metab 29 8 (1969) 1074-1082
107. Toogood J.H., Baskerville J.C., Jennings B., et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol 70 4 (1982) 288-298
108. Pincus D.J., Humeston T.R., and Martin R.J. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 100 6 (1997) 771-774
109. Kemp J.P., Berkowitz R.B., Miller S.D., et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 106 3 (2000) 485-492
110. Gaultier C., Reinberg A., and Motohashi Y. Circadian rhythm in total pulmonary resistance of asthmatic children. Effects of a beta-agonist agent. Chronobiol Int 5 3 (1988) 285-290
111. D'Alonzo G.E., Smolensky M.H., Feldman S., et al. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. Chest 107 2 (1995) 406-412
112. Faurschou P., Engel A.M., and Haanaes O.C. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 49 10 (1994) 827-832
113. Noonan M.J., Chervinsky P., Brandon M., et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 11 6 (1998) 1232-1239
114. Altman L.C., Munk Z., Seltzer J., et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol 102 1 (1998) 50-56
115. Iravani J.M. Theophylline and mucocilliary function. Chest 92 Suppl (1987) 38-43
116. Murciano D., Aubier M., Lecocguic Y., et al. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med 311 6 (1984) 349-353
117. Rafnsson V., Tulinius H., Jonasson J.G., et al. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control 12 2 (2001) 95-101
118. Mormont M.C., Waterhouse J., Bleuzen P., et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6 8 (2000) 3038-3045
119. Nakamura K.D., Duffy P.H., Lu M.H., et al. The effect of dietary restriction on myc protooncogene expression in mice: a preliminary study. Mech Ageing Dev 48 2 (1989) 199-205
120. Fu L., Pelicano H., Liu J., et al. The circadian gene period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 1 (2002) 41-50
121. Miller B.H., McDearmon E.L., Panda S., et al. Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A 104 9 (2007) 3342-3347
122. Gery S., Gombart A.F., Yi W.S., et al. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106 8 (2005) 2827-2836
123. Gery S., Komatsu N., Baldjyan L., et al. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22 3 (2006) 375-382
124. Hua H., Wang Y., Wan C., et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97 7 (2006) 589-596
125. Johansen L.M., Iwama A., Lodie T.A., et al. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol 21 11 (2001) 3789-3806
126. Matsuo T., Yamaguchi S., Mitsui S., et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science 302 5643 (2003) 255-259
127. Wang H M.S., Grachtchouk V., Zhuang D., et al. c-myc depletion inhibits proliferation of human cells at various stages of the cell cycle. Oncogene 27 (2008) 1905-1915
128. Prathapam T., Tegen S., Oskarsson T., et al. Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition. Proc Natl Acad Sci U S A 103 8 (2006) 2695-2700
129. Levi F., Focan C., Karaboue A., et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59 9-10 (2007) 1015-1035
130. Dang C.V., Gerson S.L., Litwak M., et al. Gene therapy and translational cancer research. Clin Cancer Res 5 2 (1999) 471-474
131. Lissoni P., Brivio F., Fumagalli L., et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 28 2B (2008) 1377-1381
132. Lissoni P., Chilelli M., Villa S., et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35 1 (2003) 12-15
133. Blask D.E., Brainard G.C., Dauchy R.T., et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65 23 (2005) 11174-11184
134. Pavlova M.K., Shea S.A., and Bromfield E.B. Day/night patterns of focal seizures. Epilepsy Behav 5 1 (2004) 44-49
135. Durazzo T.S., Spencer S.S., Duckrow R.B., et al. Temporal distributions of seizure occurrence from various epileptogenic regions. Neurology 70 15 (2008) 1265-1271
136. Pavlova Mk B.E., Evoniuk H., and Shea S.A. Endogenous circadian variation of epileptiform abnormalities in idiopathic generalized epilepsy. Sleep 28 Suppl (2005) S71
137. Herman S.T., Walczak T.S., and Bazil C.W. Distribution of partial seizures during the sleep-wake cycle: differences by seizure onset site. Neurology 56 11 (2001) 1453-1459
138. Yegnanarayan R., Mahesh S.D., and Sangle S. Chronotherapeutic dose schedule of phenytoin and carbamazepine in epileptic patients. Chronobiol Int 23 5 (2006) 1035-1046
139. Orr W.C., Allen M.L., and Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 89 4 (1994) 509-512
140. Lear C.S., Flanagan Jr. J.B., and Moorrees CF. The frequency of deglutition in man. Arch Oral Biol 10 (1965) 83-100
141. Schneyer L.H., Pigman W., Hanahan L., et al. Rate of flow of human parotid, sublingual, and submaxillary secretions during sleep. J Dent Res 35 1 (1956) 109-114
142. Elsenbruch S., Orr W.C., Harnish M.J., et al. Disruption of normal gastric myoelectric functioning by sleep. Sleep 22 4 (1999) 453-458
143. Orr W.C., Johnson L.F., and Robinson M.G. Effect of sleep on swallowing, esophageal peristalsis, and acid clearance. Gastroenterology 86 5 (1984) 814-819
144. Satlin A., Volicer L., Stopa E.G., et al. Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiol Aging 16 5 (1995) 765-771
145. Hu K., van Someren E.J., Shea S.A., et al. Reduction of scale-invariance of activity fluctuations with aging and Alzheimer's disease: involvement of the circadian pacemaker. Proc Natl Acad Sci USA 106 8 (2009) 2490-2494
146. Cohen-Mansfield J., Garfinkel D., and Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia-a preliminary study. Arch Gerontol Geriatr 31 1 (2000) 65-76
147. McDuff T., and Sumi S.M. Subcortical degeneration in Alzheimer's disease. Neurology 35 1 (1985) 123-126
148. Swaab D.F., Fliers E., and Partiman T.S. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 342 1 (1985) 37-44
149. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6 11 (2004) 1054-1061
150. Zhou J.N., Hofman M.A., and Swaab D.F. VIP neurons in the human SCN in relation to sex, age and Alzheimer Disease. Neurology of Aging 16 4 (1995) 571-576
151. Liu R.Y., Zhou J.N., Hoogendijk W.J., et al. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 59 4 (2000) 314-322
152. Maywood E.S., Reddy A.B., Wong G.K., et al. Synchronization and maintenance of timekeeping in suprachiasmatic circadian clock cells by neuropeptidergic signaling. Curr Biol 16 6 (2006) 599-605
153. Sheward W.J., Maywood E.S., French K.L., et al. Entrainment to feeding but not to light: circadian phenotype of VPAC2 receptor-null mice. J Neurosci 27 16 (2007) 4351-4358
154. Wu Y.H., Feenstra M.G., Zhou J.N., et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 88 12 (2003) 5898-5906
155. Wu Y.H., Fischer D.F., Kalsbeek A., et al. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock". Faseb J 20 11 (2006) 1874-1876
156. Wang J.Z., and Wang Z.F. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 27 1 (2006) 41-49
157. Lahiri D.K. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res 26 3 (1999) 137-146
158. Song W., and Lahiri D.K. Melatonin alters the metabolism of the beta-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 9 2 (1997) 75-92
159. Zhang Y.C., Wang Z.F., Wang Q., et al. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol Sin 25 4 (2004) 447-451
160. Arendt J. Melatonin and the mamallian pineal gland. 1st edition (1995), Chapman and Hall, London
161. Cardinali D.P., Brusco L.I., Liberczuk C., et al. The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 23 Suppl 1 (2002) 20-23
162. Cardinali D.P., Brusco L.I., Lloret S.P., et al. Melatonin in sleep disorders and jet-lag. Neuro Endocrinol Lett 23 Suppl 1 (2002) 9-13
163. Sasaki M., Jordan P., Joh T., et al. Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kappaB. BMC Gastroenterol 2 (2002) 9
164. Pei Z., and Cheung R.T. Pretreatment with melatonin exerts anti-inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model. J Pineal Res 37 2 (2004) 85-91
165. Feng Z., Chang Y., Cheng Y., et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 37 2 (2004) 129-136
166. Feng Z., Cheng Y., and Zhang J.T. Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J Pineal Res 37 3 (2004) 198-206
167. Riemersma-van der Lek R.F., Swaab D.F., Twisk J., et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 299 22 (2008) 2642-2655
168. Ayas N.T., White D.P., Manson J.E., et al. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med 163 2 (2003) 205-209
169. Harrison Y., and Horne J.A. The impact of sleep deprivation on decision making: a review. J Exp Psychol Appl 6 3 (2000) 236-249
170. Knutson K.L., and Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann N Y Acad Sci 1129 (2008) 287-304
171. Monk T.H. Shift work: basic principles. In: Kryger M.R.T., and Dement W.C. (Eds). Principles and practice of sleep medicine. 4th edition (2005), WB Saunders Co, Philadelphia 673-680
172. Gander P.H., Gregory K.B., Miller D.L., et al. Flight crew fatigue V: long-haul air transport operations. Aviat Space Environ Med 69 Suppl 9 (1998) B37-B48
173. Mitler M.M., Miller J.C., Lipsitz J.J., et al. The sleep of long-haul truck drivers. N Engl J Med 337 11 (1997) 755-761
174. Kawachi I., Colditz G.A., Stamfer M.J., et al. Prospective study of shift work and risk of coronary heart disease in women. Circulation 92 (1996) 3178-3182
175. Karlsson B., Alfredsson L., Knutsson A., et al. Total mortality and cause-specific mortality of Swedish shift- and dayworkers in the pulp and paper industry in 1952-2001. Scand J Work Environ Health 31 1 (2005) 30-35
176. Boggild H., Suadicani P., Hein H.O., et al. Shift work, social class, and ischaemic heart disease in middle aged and elderly men; a 22 year follow up in the Copenhagen Male Study. Occup Environ Med 56 9 (1999) 640-645
177. Oishi M., Suwazono Y., Sakata K., et al. A longitudinal study on the relationship between shift work and the progression of hypertension in male Japanese workers. J Hypertens 23 12 (2005) 2173-2178
178. Inoue M., Morita H., Inagaki J., et al. Influence of differences in their jobs on cardiovascular risk factors in male blue-collar shift workers in their fifties. Int J Occup Environ Health 10 3 (2004) 313-318
179. Knutsson A., Akerstedt T., Jonsson B.G., et al. Increased risk of ischaemic heart disease in shift workers. Lancet 328 8498 (1986) 89-92
180. Tuchsen F., Hannerz H., and Burr H. A 12 year prospective study of circulatory disease among Danish shift workers. Occup Environ Med 63 7 (2006) 451-455
181. Sgoifo A., Buwalda B., Roos M., et al. Effects of sleep deprivation on cardiac autonomic and pituitary-adrenocortical stress reactivity in rats. Psychoneuroendocrinology 31 2 (2006) 197-208
182. Yamasaki F., Schwartz J.E., Gerber L.M., et al. Impact of shift work and race/ethnicity on the diurnal rhythm of blood pressure and catecholamines. Hypertension 32 3 (1998) 417-423
183. Kitamura T., Onishi K., Dohi K., et al. Circadian rhythm of blood pressure is transformed from a dipper to a non-dipper pattern in shift workers with hypertension. J Hum Hypertens 16 3 (2002) 193-197
184. Ishizaki M Y.M., Nakagawa H., Honda R., et al. The influence of work characteristics on body mass index and waist to hip ratio in Japanese employees. Ind Health 42 (2004) 41-49
185. Niedhammer I., Lert F., and Marne M.J. Prevalence of overweight and weight gain in relation to night work in a nurses' cohort. Int J Obes Relat Metab Disord 20 7 (1996) 625-633
186. Karlsson B., Knutsson A., and Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med 58 11 (2001) 747-752
187. Nagaya T., Yoshida H., Takahashi H., et al. Markers of insulin resistance in day and shift workers aged 30-59 years. Int Arch Occup Environ Health 75 8 (2002) 562-568
188. Mikuni E., Ohoshi T., Hayashi K., et al. Glucose intolerance in an employed population. Tohoku J Exp Med 141 Suppl (1983) 251-256
189. Kroenke C.H., Spiegelman D., Manson J., et al. Work characteristics and incidence of type 2 diabetes in women. Am J Epidemiol 165 2 (2007) 175-183
190. Buxton Om S.K., and Van Cauter E. Modulation of endocrine function and metabolism by sleep and sleep loss. In: Lee-Chiong M., Carskadon M., and Sateia M. (Eds). Sleep medicine (2002), Hanley&Belfus, Inc, Philadelphia 59-69
191. Chaput J.P., Despres J.P., Bouchard C., et al. Short sleep duration is associated with reduced leptin levels and increased adiposity: results from the Quebec family study. Obesity (Silver Spring) 15 1 (2007) 253-261
192. Spiegel K., Tasali E., Penev P., et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 141 11 (2004) 846-850
193. Mullington J.M., Chan J.L., Van Dongen H.P., et al. Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. J Neuroendocrinol 15 9 (2003) 851-854
194. Spiegel K., Leproult R., L'Hermite-Baleriaux M., et al. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J Clin Endocrinol Metab 89 11 (2004) 5762-5771
195. Muoio D.M., and Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 16 4 (2002) 653-666
196. Lichnovska R., Gwozdziewiczova S., and Hrebicek J. Gender differences in factors influencing insulin resistance in elderly hyperlipemic non-diabetic subjects. Cardiovasc Diabetol 1 (2002) 4
197. Saad M.F., Khan A., Sharma A., et al. Physiological insulinemia acutely modulates plasma leptin. Diabetes 47 4 (1998) 544-549
198. Shea S.A., Hilton M.F., Orlova C., et al. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 90 5 (2005) 2537-2544
199. Gavrila A., Peng C.K., Chan J.L., et al. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 88 6 (2003) 2838-2843
200. Oliver P., Ribot J., Rodriguez A.M., et al. Resistin as a putative modulator of insulin action in the daily feeding/fasting rhythm. Pflugers Arch 452 3 (2006) 260-267
201. Ariyasu H., Takaya K., Tagami T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86 10 (2001) 4753-4758
202. Tritos N.A., Mun E., Bertkau A., et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 11 8 (2003) 919-924
203. Yannielli P.C., Molyneux P.C., Harrington M.E., et al. Ghrelin effects on the circadian system of mice. J Neurosci 27 11 (2007) 2890-2895
204. Taheri S., Lin L., Austin D., et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med 1 3 (2004) e62
205. Scheer F.A., Hilton M.F., Mantzoros C.S., et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 106 11 (2009) 4453-4458
206. Taylor P.J., and Pocock S.J. Mortality of shift and day workers 1956-68. Br J Ind Med 29 2 (1972) 201-207
207. Schernhammer E.S., Laden F., Speizer F.E., et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93 20 (2001) 1563-1568
208. Tynes T., Hannevik M., Andersen A., et al. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control 7 2 (1996) 197-204
209. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 12 1 (2001) 74-77
210. Schernhammer E.S., Laden F., Speizer F.E., et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 95 11 (2003) 825-828
211. Krstev S., Baris D., Stewart P.A., et al. Risk for prostate cancer by occupation and industry: a 24-state death certificate study. Am J Ind Med 34 5 (1998) 413-420
212. Demers P.A., Checkoway H., Vaughan T.L., et al. Cancer incidence among firefighters in Seattle and Tacoma, Washington (United States). Cancer Causes Control 5 2 (1994) 129-135
213. Hill S.M., and Blask D.E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48 21 (1988) 6121-6126
214. Cos S., Fernandez R., Guezmes A., et al. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58 19 (1998) 4383-4390
215. Cos S., Mediavilla M.D., Fernandez R., et al. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro?. J Pineal Res 32 (2002) 90-96
216. Mediavilla M.D., Cos S., and Sanchez-Barcelo E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 65 4 (1999) 415-420
217. Tamarkin L., Cohen M., Roselle D., et al. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41 11 (1981) 4432-4436
218. Tam C.W., Mo C.W., Yao K.M., et al. Signaling mechanisms of melatonin in antiproliferation of hormone refractory 22rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res 42 2 (2007) 191-202
219. Zhu Y., Brown H.N., Zhang Y., et al. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14 1 (2005) 268-270
220. Challet E., Poirel V.J., Malan A., et al. Light exposure during daytime modulates expression of Per1 and Per2 clock genes in the suprachiasmatic nuclei of mice. J Neurosci Res 72 5 (2003) 629-637
221. Caldelas I., Poirel V.J., Sicard B., et al. Circadian profile and photic regulation of clock genes in the suprachiasmatic nucleus of a diurnal mammal Arvicanthis ansorgei. Neuroscience 116 2 (2003) 583-591
222. Segawa K., Nakazawa S., Tsukamoto Y., et al. Peptic ulcer is prevalent among shift workers. Dig Dis Sci 32 5 (1987) 449-453
223. Rubin N.H., Singh P., Alinder G., et al. Circadian rhythms in gastrin receptors in rat fundic stomach. Dig Dis Sci 33 8 (1988) 931-937
224. Larsen K.R., Dayton M.T., and Moore J.G. Circadian rhythm in gastric mucosal blood flow in fasting rat stomach. J Surg Res 51 4 (1991) 275-280
225. Larsen K.R., Moore J.G., and Dayton M.T. Circadian rhythms of gastric mucus efflux and residual mucus gel in the fasting rat stomach. Dig Dis Sci 36 11 (1991) 1550-1555
226. Moore J.G., Mitchell M.D., Larsen K.R., et al. Circadian rhythm in prostacyclin activity in gastric tissue of the fasting rat. Am J Surg 163 1 (1992) 19-22
227. Moore J.G., and Goo R.H. Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man. Chronobiol Int 4 1 (1987) 111-116
228. Larsen K.R., Moore J.G., Dayton M.T., et al. Circadian rhythm in aspirin (ASA)-induced injury to the stomach of the fasted rat. Dig Dis Sci 38 8 (1993) 1435-1440
229. Goo R.H., Moore J.G., Greenberg E., et al. Circadian variation in gastric emptying of meals in humans. Gastroenterology 93 3 (1987) 515-518
230. Kumar D., Wingate D., and Ruckebusch Y. Circadian variation in the propagation velocity of the migrating motor complex. Gastroenterology 91 4 (1986) 926-930
231. Moore J.G., and Halberg F. Circadian rhythm of gastric acid secretion in men with active duodenal ulcer. Dig Dis Sci 31 11 (1986) 1185-1191
232. Larsen K.R., Moore J.G., and Dayton M.T. Circadian rhythms of acid and bicarbonate efflux in fasting rat stomach. Am J Physiol 260 4 Pt 1 (1991) G610-G614
233. Axelsson G., Rylander R., and Molin I. Outcome of pregnancy in relation to irregular and inconvenient work schedules. Br J Ind Med 46 6 (1989) 393-398
234. Mamelle N., Laumon B., and Lazar P. Prematurity and occupational activity during pregnancy. Am J Epidemiol 119 3 (1984) 309-322